Dessight Biomedical completes tens of millions in Series A2 financing to further advance in the ultra-microsurgery robotics field

Recently, Dessight Biomedical completed a Series A2 financing round amounting to tens of millions. This round was led by Fortune Capital, with continued additional investment from Panlin Capital. WinX Capital served as the exclusive financial advisor for this round. Notably, this funding follows Dessight Biomedical's previous financing round by only six months. The newly raised capital will accelerate Dessight Biomedical's efforts to advance its ultra-microsurgery robot technology from a leading innovation to widespread market adoption.

With robot-assisted micro-manipulation as its core technology, Dessight Biomedical has long been dedicated to the specialized field of ultra-microsurgery robotics. Its ultra-microsurgery robotic products are designed to surpass the physical limitations of human hands and address critical challenges faced by surgeons, representing a key solution to numerous "unmet clinical needs." This domain is widely regarded as the next blue-ocean market within the surgical robotics landscape. Dessight Biomedical not only leads the Chinese market in terms of technological sophistication and clinical progress but, more importantly, has developed high-tech-barrier robotic solutions for ophthalmology and microsurgery by genuinely prioritizing the patient's perspective and starting from real clinical demands. Its products successfully overcome the surgeon's dilemma of "seeing but not being able to operate precisely," thereby delivering profound societal value.

As a company dedicated to the development of ultra-microsurgery robotic products, Dessight Biomedical has, since its inception, consistently adhered to its founding principle of addressing clinical needs in ultra-microsurgery. It is committed to utilizing robotic-assisted technology to filter out hand tremors and achieve micron-level precision in operations.

In the Field of Ophthalmology: China has over 40 million patients with fundus retinal diseases, and the number of cataract surgeries is projected to exceed 5 million by 2025. Dessight's ultra-microsurgery technology enables more stable and precise subretinal operations. This not only effectively reduces surgical trauma but, combined with its independently developed ultra-fine injection needles—which have an outer diameter as small as 40 microns (half the diameter of a human hair)—facilitates less invasive treatments for fundus conditions. Moreover, it makes the precise delivery of many innovative drugs possible, offering renewed hope for vision restoration to a vast number of patients with eye diseases. Dessight's ophthalmic surgical robot has entered the "Green Channel" of the National Medical Products Administration (NMPA) for innovative medical device review, making it the first ophthalmic surgical robot in China to enter this expedited pathway. Concurrently, Dessight Biomedical will continue to expand the indications for its ophthalmic surgical robot, aiming to establish it as the optimal assistant for a full spectrum of ophthalmic surgeries.

In General Microsurgery: For challenging conditions such as post-cancer lymphedema, Dessight Biomedical empowers surgeons by assisting them in performing high-quality lymphaticovenous anastomosis (LVA), significantly improving surgical success rates and patients' postoperative quality of life. Dessight Biomedical has successfully completed the world's first robot-assisted deep cervical lymphaticovenous anastomosis (dcLVA) reconstruction and China's first superficial lymphaticovenous anastomosis (sLVA) procedure in the limbs, demonstrating superior stability and safety.

Currently, Dessight Biomedical has launched product series including ophthalmic surgical robots and microsurgical robots, along with offerings such as ophthalmic surgery simulation systems, instrument-holding robots, micro-injection pumps, and micro-injection needles. Dessight Biomedical continues to advance product iteration through its core technology platform. Simultaneously, Dessight Biomedical is actively pursuing a global strategy, striving to bring China-originated ultra-microsurgery technology to benefit patients worldwide.